Scientists develop novel chemical 'dye' to improve liver cancer imaging

May 2, 2017
A research team led by Assistant Professor Edward Chow (right), Principal Investigator from the Cancer Science Institute of Singapore at NUS and Department of Pharmacology at NUS Yong Loo Lin of Medicine, has developed a novel nanodiamond-based contrast agent – a chemical "dye" used to enhance the visibility of internal body structures in magnetic resonance imaging – that improves visualisation of liver cancer tumours. Credit: National University of Singapore

Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based contrast agent—a chemical "dye" used to enhance the visibility of internal body structures in magnetic resonance imaging (MRI)—that improves visualisation of liver cancer tumours. Better and more sensitive imaging contributes towards detecting liver cancer and is crucial for planning for treatment.

MRI is a medical imaging technique commonly used for diagnosis and to track the progress of patients after treatment. Currently, there are two modes of MRI imaging, T1-weighted and T2-weighted imaging, and patients are often given contrast agents to improve imaging quality. However, each imaging mode requires a specific class of contrast agent which cannot be used together. This poses a greater challenge in the diagnosis of cancer, where T2-weighted imaging is still not considered reliable, and both T1- and T2-weighted imaging can be confounded by tumour vascularity.

A research team led by Assistant Professor Edward Chow, Principal Investigator from the Cancer Science Institute of Singapore at NUS and Department of Pharmacology at NUS Yong Loo Lin of Medicine, has developed a dual-mode contrast agent which enables clearer and more accurate of tumours to be obtained in both T1- and T2-weighted MRI scans, and with lower dosages of contrast agent.

Better tumour imaging using nanodiamond-based dual-mode contrast agent

The novel dual-mode contrast agent, which was developed using nanodiamonds in combination with a manganese base, provides greater imaging contrast than existing clinical agents which are used to improve quality of MRIs. The team also found that liver tumours that are unable to be visualised without contrast agents become readily visible even at low dosages of the novel compound.

The novel contrast agent (grey solution in larger tube), developed using nanodiamonds in combination with a manganese base, provides clearer and more accurate images of liver tumours at lower dosages. Credit: National University of Singapore

Contrast agents work by altering the magnetic properties of nearby , which enhances the quality of MR images. Nanodiamonds, which are carbon-based particles of two to eight nanometres in diameter, have unique chemical properties that allow them to attract water molecules. This enables them to promote proton exchange between water molecules and paramagnetic ions (i.e. contrast agents) that accumulate in tissues. As a result, T1 and T2 relaxation is enhanced, giving better quality images. This is unlike existing nanotechnology-based approaches, where nanomaterials are used to improve delivery of paramagnetic ions to specific tumour sites.

"Our experiments suggest that our dual-mode contrast agent holds great promise in improving imaging for liver cancer. We are hopeful that this advancement in nanomedicine will lead to safer and more accurate diagnosis of . Moving forward, we plan to conduct further prepreclinical safety studies for our agents, with the end goal being clinical implementation. We are also looking into using our to improve imaging for glioma and ovarian cancer," said Asst Prof Chow.

Explore further: Using sugar to detect malignant tumours

More information: Weixin Hou et al. Nanodiamond–Manganese dual mode MRI contrast agents for enhanced liver tumor detection, Nanomedicine: Nanotechnology, Biology and Medicine (2017). DOI: 10.1016/j.nano.2016.12.013

Related Stories

Using sugar to detect malignant tumours

February 22, 2016
Ordinary sugar could become a contrast agent of the future for use in magnetic resonance tomography examinations of tumours. Malignant tumours show higher sugar consumption than surrounding tissue.

Sharper imaging would promote earlier diagnosis of malignancies

November 18, 2016
A common chemical element embedded in a tiny bubble of fat has the potential to advance cancer imaging. In a study of pet dogs that were biopsied for cancer, a new contrast agent used in CT imaging allowed veterinarians to ...

Multiple sclerosis: Reduced levels of contrast agent deposits in the brain

December 12, 2016
Gadolinium, one of the rare earth elements, is used as a contrast agent that enhances the quality of MRI examinations of internal organs and tissues. Researchers from Charité - Universitätsmedizin Berlin (NeuroCure Clinical ...

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.